22 15355 Lambda Drive 23 STCBM 2.100.05 24 San Antonio, TX 78245 25 Phone: (210) 562-6117 26 Tau protein accumulation is the most common pathology among degenerative brain 27 diseases, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), 28 traumatic brain injury (TBI) and over twenty others 1 . Tau-containing neurofibrillary tangle 29 (NFT) accumulation is the closest correlate with cognitive decline and cell loss, yet the 30 mechanisms mediating tau toxicity are poorly understood. NFT-containing neurons do 31 not die, which suggests secondary mechanisms are driving toxicity 2 . We evaluated gene 32 expression patterns of NFT-containing neurons microdissected from AD patient brains 3 33 and found they develop an expression profile consistent with cellular senescence 34 described in dividing cells. This complex stress response induces a near permanent cell 35 cycle arrest, adaptations to maintain survival, cellular remodeling, and metabolic 36 dysfunction 4 . Moreover, senescent cells induce chronic degeneration of surrounding 37 tissue through the secretion of pro-inflammatory, pro-apoptotic molecules termed the 38 senescence-associated secretory phenotype (SASP) 5 . Using transgenic mouse models of 39 tau-associated pathogenesis we found that NFTs induced a senescence-like phenotype 40 including DNA damage, karyomegaly, mitochondrial dysfunction and SASP. Cdkn2a 41 transcript level, a hallmark measure of senescence, directly correlated with brain atrophy 42 and NFT load. This relationship extended to postmortem brain tissue from humans with 43 PSP to indicate a phenomenon common to tau toxicity. Tau transgenic mice with late 44 stage pathology were treated with senolytics to remove senescent cells. Despite the 45 advanced age and disease progression, senolytic treatment reduced total NFT burden, 46 neuron loss and ventricular enlargement; and normalized cerebral blood flow to that of 47 non-transgenic control mice. Collectively, these findings indicate that NFTs induce 48 cellular senescence in the brain, which contributes to neurodegeneration and brain 49 dysfunction. Moreover, given the prevalence of tau protein deposition among 50 neurodegenerative diseases, these findings have broad implications for understanding, 51 and potentially treating, dozens of brain diseases.
, b). Examination of the hydrolase coding gene, galactosidase beta (β) 1 (Glb1),
140
(Extended Data Figure 4c ) revealed that tau NFT mice expressed higher Glb1 gene expression 141 than controls, yet fewer tau NFT hippocampal neurons displayed β−gal hydrolase activity at pH 142 6.0. Further, the number of SA β−gal reactive cells was positively correlated with brain mass 143 (R 2 : 0.4852, P = 0.0039 Extended Data Figure 4 ). Collectively, these results suggest that tau NFT -144 induced β−gal gene upregulation did not alter activity at pH 6.0, nor contribute to brain atrophy.
145
Senescent cells exert toxicity to adjacent cells and tissue through the release of toxic secreted 146 molecules. To determine if the NFT-induced SASP-associated profile (Figure 1 ) affected the 147 surrounding neuronal microenvironment, we performed distance analyses between 148 histologically normal neurons (absence of NFTs), between normal neurons and NFTs, and 149 between NFTs. The distance between neurons was significantly increased in the presence of 150 NFTs (P < 0.0001, Figure 3c , f). Specifically, the distance between a non-NFT and NFT, or 151 between two NFTs was greater than two non-NFT neurons (P < 0.0001; 1.6-and 1.5-fold, respectively). Collectively, these results led us to conclude that NFTs induced DNA damage, 153 nuclear hypertrophy, and altered the surrounding neuronal microenvironment.
154
Permanent cell cycle arrest is a hallmark of cellular senescence, and it is induced by DNA 155 damage, oxidative stress and SASP 4 . A recent study reported that DNA damaging agents 156 associated with Parkinson's disease could induce a senescence-like phenotype in astrocytes 21 .
157
Notably, decreased nuclear lamin B1 expression, the marker used to identify astrocyte 158 senescence in vivo 21 , also occurs in AD 22 . In AD and tau transgenic animals, decreased lamin 159 B1 is specific to tau-containing neurons where it causes relaxation of heterochromatin and 160 activates the cell cycle 22 , all of which are features of cellular senescence. Aberrant neuronal cell 161 cycle activity induces AD pathology and neurodegeneration 23 . The cell cycle protein p21, 162 encoded by Cdkn1a, is upregulated in many senescent cell types and has been associated with 163 DNA damage during neuronal aging 24 . We found that tau NFT brains expressed 3-fold higher 164 Cdkn1a than tau WT mice (P = 0.0178, Figure 3g ); this was replicated in a separate mouse cohort 165 (P = 0.0086, Extended Data Figure 5a ). Elevated expression of the cyclin dependent kinase 166 inhibitor 2a, Cdkn2a, is one of the most robust markers of cellular senescence, and its protein 167 product, p16 INK4A , co-localizes with NFTs in human AD 25 . Anti-p16 INK4A antibodies are notoriously 168 poor in mouse tissue, so we exclusively measured Cdk2na gene expression. Tau NFT Cdkn2a 169 forebrain expression was 2.7-and 2.6-fold higher than CTL and tau WT , respectively (P = 0.0303 170 and P = 0.0352, respectively; Figure 3h ); this effect was replicated in an independent mouse 171 cohort (P = 0.0016, Extended Data Figure 5b ). Similar to mitochondrial dysfunction, genotype-172 specific changes in Cdkn2a were not found in the cerebellum, a brain region without transgenic 173 tau expression or NFTs, indicating that the pathogenic tau microenvironment was required for 174 Cdkn2a upregulation (Extended Data Figure 5c ). Further, when plotted against brain weight,
175
Cdkn2a expression was a strong predictor of brain atrophy across mouse lines (P < 0.0001, R 2 176 = 0.5615; Figure 3i ; and tau NFT mice plotted alone: P = 0.0158, R 2 = 0.5885; Extended Data 177 Figure 5d ). These data connect NFTs, Cdkn2a and neurodegeneration. density, NFT onset, or merely protein accumulation, we pursued multiple genetic approaches 180 and a pharmacological intervention. Genetic deletion of endogenous mouse tau (microtubule 181 associated protein tau, Mapt, knockout) reduced soluble and insoluble tau expression, 182 decreased NFT pathology and neurodegeneration in tau NFT mice 26 (tau NFT -Mapt 0/0 ). The reduced 183 tau pathology corresponded with 60% lower Cdkn2a expression (P = 0.0041, Figure 3j ), 184 decreased SASP (Extended Data Figure 6 ) and correlated with decreased brain atrophy (tau NFT -
185
Mapt 0/0 : 0.4058 ± 0.009 versus age-matched tau NFT Mapt wt/wt : 0.3451 ± 0.0116; 17.5% 186 difference, P = 0.0143). Because tau NFT mice develop aggressive tauopathy with NFT formation 187 in early life, we focused on tau WT mice between 16-28-months-old to detect subtle cellular 188 changes associated with different stages of NFT development and progression. We found that
189
Cdkn2a gene expression increased significantly during this age interval, and at 28 months of 190 age tau WT Cdkn2a expression was similar to that of 16-month-old tau NFT 
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To then determine whether these findings translated to human brains with pure tauopathy (i.e.,
202
NFT pathology without other protein aggregates such as Aβ), we acquired human brain tissue with histopathologically confirmed progressive supranuclear palsy (PSP) (Extended Data Table   204 1 for patient characteristics). PSP is an age-associated tauopathy that clinically manifests as 205 parkinsonism with additional motor abnormalities and cognitive dysfunction 1 , and is 
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The intermittent senolytic dosing schedule allows for rapid drug clearance, instead of 236 chronic activation of molecular targets/pathways common among many therapeutic strategies.
237
To determine if cyclic senescent cell removal produced long-lasting global effects on brain, we 238 used MRI to analyze anatomical structure and cerebral blood flow, a functional defect that 239 occurs in AD and tau NFT mice and is closely associated with cognitive impairment 31 . Pathogenic Figure 4l ). Brain atrophy progresses with age in tau NFT -Mapt 0/0 mice, and was evidenced 257 by a 9.8% decrease in brain volume in tau NFT -Mapt 0/0 vehicle treated mice compared to CTLs (P 258 = 0.0026, Extended Data Figure 8 ). However, a significant difference in brain volume between 259 CTLs and tau NFT Mapt 0/0 mice that received DQ was not observed. Closer evaluation of brain 260 regions revealed that this effect was driven by cortical atrophy. While subcortical brain region 261 volume did not differ among groups, cortical volume of vehicle treated tau NFT -Mapt 0/0 mice was 262 31% lower than controls; DQ mitigated this effect (P = 0.0092 and P = 0.0274, vehicle and DQ, 263 respectively; Extended Data 8a, b). Overall, the composite effect of DQ treatment in tau NFT mice 264 was a significant global benefit (P = 0.0138; Figure 4m ); targeting cellular senescence reduced 265 total NFT burden and SASP expression, enhanced neuronal protein expression, and benefited 266 overall tissue structure and cerebral blood flow in a late-life, advanced stage AD mouse model.
267
The inability to effectively treat tau-associated diseases arises, in part, from a limited 268 understanding of processes driving neurodegeneration during the prodromal period. We have 269 identified cellular senescence, the quintessence of latent tissue degeneration, as a cellular Findings from GDS2795 were replicated with more stringent criteria (p < 0.05 for NFT/CTL 308 ratios with no fold change limit) allowing for 1715 genes to be uploaded into IPA with similar 309 results. Similarly, these findings were replicated a third time using the LIMMA package, the most 310 common method for microarray analysis. This method did not take into account within subjects 311 design. Using a P < 0.05, 1219 differentially regulated genes were uploaded for IPA analyses;
312 the results were similar to the original findings. Furthermore, results from GSE56772 were 313 replicated using Gene Set Enrichment Analysis (GSEA) with default setting and similar results 314 were obtained.
315
RNA extraction and qPCR. Frozen forebrain and cerebellum were powdered in liquid nitrogen.
316
RNA was extracted from ~25mg of each respective brain (or brain region) using the RNAqueous
317
4PCR® kit (Ambion), following the manufacturer protocol including the 15 minute DNase 
329
Cycle profile was performed using the kit manufacturer protocol.
330
Protein extraction and capillary electrophoresis. 50mg frozen forebrain was used for 331 subcellular fractionation and capillary electrophoresis as previously described 28 protein concentration 37,38 ; (Extended Data Figure 9 ).
343
Histology. Brains were fixed in 4% PFA for 48 hours, transferred to PBS containing 0.02% 344 sodium azide and vibratome sectioned at 30µm. Sections were washed 3x with TBS (pH 7.4),
345
and incubated in 50% ethanol for 5 mins; followed by 70% ethanol for 5 minutes. The sections 346 were then submerged in 0.7% sudan black b dissolved in 70% ethanol for 5 minutes to quench 347 lipofuscin-like autofluorescence. Tissues were then rinsed 3 times for 1-2 min in 50% ethanol.
348
Following this step, tissue sections were transferred from 50% ethanol to TBS and proceeded to 349 immunofluorescence staining as described previously 28, 36 . Primary antibodies used: PHF1
350
( 580 references unique to these sections appear only in the online paper.
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